רדאר קליני AI | ||
|---|---|---|
הניסוי הקליני NCT06855485 (ZEUS) עבור ציסטה מדומה לבלבית הוא מגייס. לכל הפרטים, עיינו בתצוגת הכרטיסים של רדאר ניסויים קליניים ובכלי הגילוי של AI. אפשר גם לשאול כל דבר כאן. | ||
Efficacy and Safety of HANAROSTEN® HOT Plumber™ With Z-EUSIT™ for Pancreatic Pseudocyst Drainage (ZEUS) 20 תצפיתי
The goal of this prospective, single-center observational study is to evaluate the safety and effectiveness of the HANAROSTEN® HOT Plumber™ with Z-EUSIT™ for draining pancreatic pseudocysts.
The main questions the study aims to answer are:
- Does the device reduce the size of pancreatic pseudocysts by at least 50% and improve associated symptoms within 30 to 60 days?
- Can the stent be successfully placed, retained...
This prospective, single-center observational study aims to evaluate the safety and effectiveness of the HANAROSTEN HOT Plumber with Z-EUSIT for pancreatic pseudocyst drainage. The study will assess clinical success, defined as a reduction of at least 50% in pseudocyst size accompanied by symptom improvement, as well as technical success, device retention, lumen patency, and adverse events. Foll...
הצג עודA Prospective Single-Center Observational Study on the Evaluation of Efficacy and Safety of HANAROSTEN® HOT Plumber™ With Z-EUSIT™ for Pancreatic Pseudocysts Drainage
- ZEUS
- ZEUS-PPD-001
Endosonography
Drainage
Stents
| קבוצת משתתפים/זרוע | התערבות/טיפול |
|---|---|
ניסיSingle Intervention Group Participants will undergo endoscopic ultrasound-guided drainage of pancreatic pseudocysts using the HANAROSTEN® HOT Plumber™ with Z-EUSIT™. | HANAROSTEN® HOT Plumber™ with Z-EUSIT™ An electrocautery-enhanced lumen-apposing metal stent designed for the drainage of pancreatic pseudocysts. The stent is delivered using a system that allows for single-step deployment without the need for guidewire exchanges or tract dilation. |
| מדד תוצאה | תיאור המדידה | טווח זמן |
|---|---|---|
Clinical Success | Reduction of pancreatic pseudocyst size by at least 50% with improvement in associated symptoms. | Within 30 or 60 days after stent placement |
| מדד תוצאה | תיאור המדידה | טווח זמן |
|---|---|---|
Technical Success - Stent Placement | Successful deployment of the stent at the intended site. | During procedure |
Technical Success - Stent Removal | Successful removal of the stent after pseudocyst resolution, confirmed by endoscopic confirmation of complete stent removal without residual fragments. | Within 30 or 60 days after placement |
Stent Retention | Retention of the stent in the intended location without migration until removal. | Within 30 or 60 days after placement |
Lumen Patency | Maintenance of an open lumen allowing fluid drainage until stent removal. | Within 30 or 60 days after placement |
Procedure Duration | Time from initial needle puncture to full deployment of the stent. | During procedure |
Adverse Events | Incidence of complications such as bleeding, infection, perforation, stent migration, tissue injury, or other adverse events. | From procedure day until one month after stent removal |
- Must be 18 years or older
- Diagnosed with pancreatic or peripancreatic pseudocyst or walled-off necrosis (with less than 30% solid components)
- Eligible for endoscopic ultrasound-guided drainage
- Able to provide informed consent and comply with study procedures
- Younger than 18 years old
- Pseudocysts with the following characteristics:
- Immature pseudocyst
- Cystic neoplasm
- Pseudoaneurysm
- Multiple pseudocysts requiring drainage
- Uncontrolled coagulation disorders:
- INR > 1.5
- Platelet count < 50,000/mm³
- Other bleeding disorders
- Ineligibility for EUS-guided drainage due to anatomical or technical reasons
- History of anaphylactic reaction to stent materials
- Pregnant or potentially pregnant women
- Current participation in another clinical trial that may affect study outcomes
Seoul